Keybank National Association Biomarin Pharmaceutical Inc Transaction History

Keybank National Association

$23.9 Billion
Q1 2024

A detailed history of Keybank National Association transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Keybank National Association holds 560,479 shares of BMRN stock, worth $46.1 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares

560,479

Previous 620,958 9.74%

Holding current value

$46.1 Million

Previous $59.9 Million 18.24%

% of portfolio

0.2%

Previous 0.27%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$83.81 - $99.0 $5.07 Million - $5.99 Million	-60,479 Reduced 9.74%	560,479 $49 Million
Q4 2023 Feb 13, 2024	BUY	$76.22 - $98.51 $767,687 - $992,192	10,072 Added 1.65%	620,958 $59.9 Million
Q3 2023 Nov 08, 2023	BUY	$85.07 - $94.48 $1.78 Million - $1.97 Million	20,884 Added 3.54%	610,886 $54.1 Million
Q2 2023 Aug 01, 2023	BUY	$86.68 - $100.3 $2.51 Million - $2.9 Million	28,952 Added 5.16%	590,002 $51.1 Million
Q1 2023 May 10, 2023	BUY	$87.74 - $117.27 $2.46 Million - $3.29 Million	28,014 Added 5.26%	561,050 $54.6 Million

Q4 2022 Jan 31, 2023	BUY	$80.93 - $108.63 $2.73 Million - $3.67 Million	33,769 Added 6.76%	533,036 $55.2 Million
Q3 2022 Oct 27, 2022	BUY	$82.16 - $96.94 $2.38 Million - $2.81 Million	29,027 Added 6.17%	499,267 $42.3 Million
Q2 2022 Aug 08, 2022	BUY	$71.48 - $86.85 $6.39 Million - $7.76 Million	89,340 Added 23.45%	470,240 $39 Million
Q1 2022 Apr 28, 2022	BUY	$74.28 - $92.69 $5.66 Million - $7.06 Million	76,189 Added 25.0%	380,900 $29.4 Million
Q4 2021 Feb 07, 2022	BUY	$71.72 - $91.47 $8.98 Million - $11.5 Million	125,229 Added 69.77%	304,711 $26.9 Million
Q3 2021 Nov 08, 2021	BUY	$74.77 - $85.47 $230,216 - $263,162	3,079 Added 1.75%	179,482 $13.9 Million
Q2 2021 Aug 12, 2021	BUY	$75.51 - $84.79 $1.26 Million - $1.41 Million	16,632 Added 10.41%	176,403 $14.7 Million
Q1 2021 May 07, 2021	BUY	$74.73 - $90.69 $7.05 Million - $8.55 Million	94,281 Added 143.96%	159,771 $12.1 Million
Q4 2020 Feb 09, 2021	BUY	$72.61 - $90.2 $3.89 Million - $4.83 Million	53,541 Added 448.08%	65,490 $5.74 Million
Q3 2020 Oct 29, 2020	BUY	$71.87 - $131.03 $143,811 - $262,191	2,001 Added 20.11%	11,949 $909,000
Q2 2020 Aug 10, 2020	BUY	$79.55 - $124.22 $143,190 - $223,596	1,800 Added 22.09%	9,948 $1.23 Million
Q1 2020 May 13, 2020	SELL	$71.37 - $96.85 $110,480 - $149,923	-1,548 Reduced 15.97%	8,148 $689,000
Q4 2019 Feb 05, 2020	BUY	$64.27 - $86.37 $623,161 - $837,443	9,696 New	9,696 $820,000
Q3 2019 Nov 04, 2019	SELL	$67.4 - $85.11 $253,019 - $319,502	-3,754 Closed	0 $0
Q2 2019 Aug 01, 2019	SELL	$80.35 - $93.9 $215,498 - $251,839	-2,682 Reduced 41.67%	3,754 $322,000
Q1 2019 May 08, 2019	SELL	$84.2 - $98.62 $65,423 - $76,627	-777 Reduced 10.77%	6,436 $572,000
Q4 2018 Jan 30, 2019	BUY	$80.14 - $106.07 $130,868 - $173,212	1,633 Added 29.27%	7,213 $614,000
Q3 2018 Nov 08, 2018	SELL	$93.92 - $105.72 $480,400 - $540,757	-5,115 Reduced 47.83%	5,580 $541,000
Q2 2018 Aug 08, 2018	BUY	$76.01 - $99.03 $441,770 - $575,562	5,812 Added 119.03%	10,695 $1.01 Million
Q1 2018 May 15, 2018	SELL	$77.67 - $92.63 $103,223 - $123,105	-1,329 Reduced 21.39%	4,883 $396,000
Q4 2017 Feb 08, 2018	SELL	$80.76 - $95.13 $128,731 - $151,637	-1,594 Reduced 20.42%	6,212 $554,000
Q3 2017 Nov 02, 2017	BUY	$80.6 - $94.95 $228,581 - $269,278	2,836 Added 57.06%	7,806 $727,000
Q2 2017 May 14, 2018	SELL	N/A	-2,803 Reduced 36.06%	4,970 $451,000
Q1 2017 May 14, 2018	BUY	N/A	1,895 Added 32.24%	7,773 $682,000
Q4 2016 May 14, 2018	BUY	N/A	5,878	5,878 $487,000

Others Institutions Holding BMRN

# of Institutions

623

Shares Held

181M

Call Options Held

1.73M

Put Options Held

1.73M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $15.3B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Keybank National Association, based on Form 13F filings with the SEC.

News

Stay updated on Keybank National Association with notifications on news.

Account

Keybank National Association Biomarin Pharmaceutical Inc Transaction History